Literature DB >> 3838398

Effect of molsidomine on cardiac preload, coronary artery diameter, and coronary resistance.

E Bassenge, U Pohl.   

Abstract

The vascular and hemodynamic effects of a single intravenous bolus injection of molsidomine (100 micrograms/kg) were studied in six chronically instrumented, conscious dogs. At this dose only a minimal, short-term effect on peripheral resistance was observed. However, there was a pronounced dilation of peripheral veins and a simultaneous increase of effective vascular compliance of more than 60%. At the same time, central blood volume decreased significantly (17%). Because of preload reduction, left ventricular end-diastolic volume and pressure decreased significantly for more than 1 hour. A significant increase of large coronary artery diameter (up to 7% occurred simultaneously. Coronary resistance vessels were not affected. All effects reached a maximum between 15 and 30 minutes and were observed for at least 4 hours. We conclude that molsidomine exerts a long-lasting effect on the large coronary arteries and on the peripheral venous system. As a result of the combined effects on cardiac preload and on epicardial artery conductance, the myocardial oxygen supply and the supply/demand ratio will be improved.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3838398     DOI: 10.1016/0002-8703(85)90667-2

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  2 in total

1.  Cardiovascular actions of a novel NO-independent guanylyl cyclase stimulator, BAY 41-8543: in vivo studies.

Authors:  Johannes-Peter Stasch; Klaus Dembowsky; Elisabeth Perzborn; Elke Stahl; Matthias Schramm
Journal:  Br J Pharmacol       Date:  2002-01       Impact factor: 8.739

2.  Effects of SIN-1 on peripheral hemodynamics and viscoelastic properties of aorta in anesthetized rabbits.

Authors:  A Friggi; H Bodard; F P Berenger; F Esclapez; P H Rolland
Journal:  Cardiovasc Drugs Ther       Date:  1989-06       Impact factor: 3.727

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.